JAMA Network
About The Study: Among patients with Tourette syndrome, ecopipam, a selective dopamine D1 receptor antagonist, maintained tic suppression and was well tolerated for up to 24 weeks, without clinically significant metabolic or movement disorder adverse effects.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
